CMO Cobra Biologics says North America is an obvious place to look at for a facility acquisition.

Catalent says making its technology available to industry will not affect its competitive edge.

Bend Research is “actively” hunting new partnerships similar to its recent alliance with Dow.

Sartorius Stedim says its new range of sterilising-grade filters can allow steam cleaning in dry conditions and minimises protein binding.

Submitting a REMS (Risk Evaluation and Mitigation Strategies) proposal for risky drug developments could earn companies brownie points, according to Quintiles’ Ed Tabor.

A bigger initial pay-out for REMS means long-term profitability for drugsmakers, says Quintiles Ed Tabor.

Developments in single-use technology signals the end for clean-in-place biomanufacturing methods, according to ThermoFisher’s Bill Whitford.

Reduce changeover time on oral solid dose machinery by cleaning equipment offline, Fette Compacting urged drugsmakers at this year’s Interphex.

SGS has added formulation development to its service offering through the expansion of its laboratory in Illinois.